However, there are some ongoing clinical trials combining fadraciclib (multi‐CDK2, 9 inhibitor) and ABT‐199 against relapsed/refractory CLL (NCT03739554), relapsed/refractory acute myeloid leukemia and myelodysplastic syndrome patients (NCT04017546) [80] which will shed light on this field. The gene discussed is CDK2; the disease is B-cell chronic lymphocytic leukemia.